For anyone who is looking for further information on puberty blockers, transitioning children and the effectiveness of current treatment plans, I have some links. I will link them over multiple posts.
1. The Dutch Model is falling apart
By Stella O'Malley / 2 January 2023
First, Stella O’Malley writes about an article in Nederlands that is throwing a great deal of light on the Dutch Protocol. It also seems that there will be a review of the patients that the Dutch team had not previously included in their papers.
This article in the Nederlands points out the dangers on only using a nation’s own sources with no international input or even wide review.
genspect.org/the-dutch-model-is-falling-apart/
2 . SEGM has published on Colin Wright’s substack a version of their previously published article.
5 False Assumptions Behind Youth Gender Transitions
2nd Jan 2023
www.realityslaststand.com/p/5-false-assumptions-behind-youth
Here is the original
segm.org/false-assumptions-gender-affirmation-minors
( segm.org )
[This reviewed Stephen M. Rosenthal‘s paper in Nature, 10 August 2021:
“Challenges in the care of transgender and gender-diverse youth: an endocrinologist’s view”
www.nature.com/articles/s41574-021-00535-9 ]
The five unproven assumptions are:
Unproven Assumption 1: Gender identity, which underlies gender dysphoria, is a fundamental personal characteristic that is biologically “ingrained.”
Unproven Assumption 2: The sharp rise in the number of youth presenting with gender dysphoria does not signal a true increase in cases—it’s merely better detection.
False Assumption 3: Medical interventions in gender-dysphoric minors have clear eligibility criteria.
False Assumption 4: Medical interventions for gender dysphoric minors have been demonstrated to be safe and effective.
Unproven Assumption 5: Detransition does not represent medical harm and is rare.
3 . This has then had quite a few interesting links.
www.tandfonline.com/doi/full/10.1080/0092623X.2022.2160396?src=
Some Limitations of “Challenges in the Care of Transgender and Gender-Diverse Youth: An Endocrinologist’s View”
from J. Cohn, Published online: 24 Dec 2022
Abstract:
There is significant disagreement about how to support trans-identified or gender-dysphoric young people. Different experts and expert bodies make strikingly different recommendations based upon the same (limited) evidence. The US-originating “gender-affirmative” model emphasizes social transition and medical intervention, while some other countries, in response to evidence reviews of medical intervention outcomes, have adopted psychological interventions as the first line of treatment. A proposed model of gender-affirming care, comprising only medical intervention for “eligible” youth, is described in Rosenthal (2021). Determining eligibility for these medical interventions is challenging and engenders considerable disagreement among experts, neither of which is mentioned. The review also claims without support that medical interventions have been shown to clearly benefit mental health, and leaves out significant risks and less invasive alternatives. The unreliability of outcome studies and the corresponding uncertainties as to how gender dysphoria develops and responds to treatment are also unreported.
4 . Then there was this review of US Military health insurance records for transition persistence. The figures simply don't seem to match what the activists want people to believe. There is something really dishonest that seems to be happening where detransition is constantly being minimised despite it appearing in unrelated studies as always being much higher than the activist figures of 1 or 2%.
academic.oup.com/jcem/article-abstract/107/9/e3937/6572526?redirectedFrom=fulltext&login=false
”Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults”
Christina M Roberts,
David A Klein, Terry A Adirim,
Natasha A Schvey, Elizabeth Hisle-Gorman
22 April 2022
Results
The study sample included 627 transmasculine and 325 transfeminine individuals with an average age of 19.2 ± 5.3 years. The 4-year gender-affirming hormone continuation rate was 70.2% (95% CI, 63.9-76.5). Transfeminine individuals had a higher continuation rate than transmasculine individuals 81.0% (72.0%-90.0%) vs 64.4% (56.0%-72.8%). People who started hormones as minors had higher continuation rate than people who started as adults 74.4% (66.0%-82.8%) vs 64.4% (56.0%-72.8%). Continuation was not associated with household income or family member type. In Cox regression, both transmasculine gender identity (hazard ratio, 2.40; 95% CI, 1.50-3.86) and starting hormones as an adult (hazard ratio, 1.69; 95% CI, 1.14-2.52) were independently associated with increased discontinuation rates.
5. .Here is another study and review of the 'Dutch Protocol':
The Myth of “Reliable Research” in Pediatric Gender Medicine: A critical evaluation of the Dutch Studies—and research that has followed
E. Abbruzzese, Stephen B. Levine, Julia W. Mason
www.tandfonline.com/doi/full/10.1080/0092623X.2022.2150346
Our analysis of the Dutch protocol has been written with three goals in mind. First, we wanted to definitively refute the claims that the foundational Dutch research represents “solid prospective research” that provides reliable evidence of net benefits of youth gender transition. In fact, it is much better described as case series—one of the lowest levels of evidence available (Dekkers et al., Citation2012, Mathes & Pieper, Citation2017). Second, we aimed to demonstrate that the type of non-comparative, short-term research that the gender medicine establishment continues to pursue is incapable of generating reliable information. And third and most importantly, we wanted to remind the medical community that medicine is a double-edged sword capable of both much good and much harm. The burden of proof—demonstrating that a treatment does more good than harm—is on those promoting the intervention, not on those concerned about the harms. Until gender medicine commits to conducting high quality research capable of reliably demonstrating the preponderance of benefits over harms of these invasive interventions, we must be skeptical of the enthusiasm generated by headlines claiming that yet another “gender study” proved benefits of transitioning youth. This time-honored concern about risk/benefit ratio is a sobering reminder that the history of medicine is replete with examples of “cures” which turned out to far more harmful than the “disease.”
6 the NICE finding stating clearly that there is little evidence that the current treatments are improving the lives of the children they are being used to treat.
arms.nice.org.uk/resources/hub/1070905/attachment
The summary of the conclusion is
Conclusion
The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.